Role of immunohistochemical detection of lymph-node metastases in management of breast cancer

BACKGROUND This study was designed to ascertain whether immunohistochemical methods could improve the detection of metastases in primary breast-cancer patients whose axillary lymph nodes were classified, by conventional methods, as disease free. METHODS Ipsilateral lymph nodes (negative for metastases by routine histology) from 736 patients (participants in Trial V of the International [Ludwig] Breast Cancer Study) were examined by serial sectioning and staining with haematoxylin and eosin (two sections from each of six levels) and by immunohistochemistry of a single section (with two anticytokeratins AE-1 and CAM 5.2). After median follow-up of 12 years, disease-free and overall survival were estimated by Kaplan-Meier methods. FINDINGS Occult nodal metastases were detected by serial sectioning and haematoxylin and eosin in 52 (7%) of 736 patients and by immunohistochemistry in 148 (20%). Only two (3%) of 64 invasive lobular or mixed invasive lobular and ductal cancers had node micrometastases, detected by haematoxylin and eosin, compared with 25 (39%) by immunohistochemistry. Occult metastases, detected by either method, were associated with significantly poor disease-free and overall survival in postmenopausal but not in premenopausal patients. Immunohistochemically detected occult lymph-node metastases remained an independent and highly significant predictor of recurrence even after control for tumour grade, tumour size, oestrogen-receptor status, vascular invasion, and treatment assignment (hazard ratio 1.79 [95% CI 1.17-2.74], p=0.007). INTERPRETATION The immunohistochemical examination of ipsilateral axillary lymph nodes is a reliable, prognostically valuable, and simple method for the detection of occult nodal metastases. Immunohistochemistry is recommended as a standard method of node examination in postmenopausal patients.

[1]  C. Redmond,et al.  Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update , 1983, Cancer.

[2]  J. Coindre,et al.  Micrometastases to axillary lymph nodes from carcinoma of breast: detection by immunohistochemistry and prognostic significance. , 1987, British Journal of Cancer.

[3]  A. Lee,et al.  Occult axillary lymph node metastases in "node-negative" breast carcinoma. , 1993, Human pathology.

[4]  M. Zelen,et al.  Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. , 1989, The New England journal of medicine.

[5]  Umberto Veronesi,et al.  Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes , 1997, The Lancet.

[6]  O. Saphir,et al.  Obscure axillary lymph‐node metastasis in carcinoma of the breast , 1948, The American journal of pathology.

[7]  S. Braun,et al.  Re: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. , 1996, Journal of the National Cancer Institute.

[8]  J. Sloane,et al.  Micrometastases in breast cancer: long-term follow-up of the first patient cohort. , 1991, European journal of cancer.

[9]  M L Lesser,et al.  Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Screening for human immunodeficiency virus infections. , 1989, The New England journal of medicine.

[11]  Internationalludwigbreastcanc Prognostic importance of occult axillary lymph node micrometastases from breast cancers , 1990 .

[12]  O. Saphir,et al.  Obscure axillary lymph node metastases in carcinoma of the breast. , 1948, The Proceedings of the Institute of Medicine of Chicago.

[13]  D. Neuberg,et al.  Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  D. Sedmak,et al.  Prognostic significance of cytokeratin-positive breast cancer metastases. , 1989, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[15]  J. Izbicki,et al.  Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  C. V. D. van de Velde,et al.  Micrometastases and survival in stage II colorectal cancer. , 1998, The New England journal of medicine.

[17]  A. Cochran,et al.  Occult Tumor Cells in the Lymph Nodes of Patients with Pathological Stage I Malignant Melanoma An Immunohistological Study , 1988, The American journal of surgical pathology.

[18]  T. Powles,et al.  DETECTION OF MICROMETASTASES IN PATIENTS WITH PRIMARY BREAST CANCER , 1983, The Lancet.

[19]  R. Cote,et al.  Antigen Retrieval Immunohistochemistry: Past, Present, and Future , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[20]  J. Forbes,et al.  Present and future projects of the international breast cancer study group , 1994, Cancer.

[21]  A. Niendorf,et al.  Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. , 1997, The New England journal of medicine.

[22]  W. McGuire,et al.  Prognostic factors in breast cancer. , 1989, Seminars in surgical oncology.

[23]  J. Tjandra,et al.  Detection and significance of occult metastases in node‐negative breast cancer , 1993, The British journal of surgery.